AI Article Synopsis
- Neutrophils display a diverse range of functions and responses, prompting increasing scientific interest in understanding this variability.
- A study by Li et al. highlights the role of a transcriptional repressor called DREAM in controlling how neutrophils adhere to blood vessel walls and migrate into tissues.
- This research sheds light on the underlying mechanisms contributing to the diverse responses of neutrophils during inflammation.
Article Abstract
Neutrophil functions and responses are heterogeneous, and the nature and categorization of this heterogeneity is achieving considerable interest. Work by Li et al. in this issue of JEM (2021. J. Exp. Med.https://doi.org/10.1084/jem.20211083) identifies how a transcriptional repressor, DREAM, regulates adhesion of neutrophils to endothelial cells and their transmigration into tissue. This study offers a mechanism for heterogeneity in this critical response of neutrophils to inflammatory stimuli.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679798 | PMC |
| http://dx.doi.org/10.1084/jem.20212141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Noninvasive and simultaneous quantitative analysis of multiple human blood components based on the grey analysis system.
Spectrochim Acta A Mol Biomol Spectrosc
February 2023
Tianjin University, State Key Laboratory of Precision Measurement Technology and Instruments, China. Electronic address:
Noninvasive detection of human blood components is the dream of human beings and the goal of clinical detection. From the perspective of mathematical analysis, based on the grey analysis system, the principle of spectral chemical quantitative analysis and the solution method of multivariate linear equation, this paper pioneers the spectrum elimination method, and obtains a complete, high-precision, synchronous and noninvasive detection system for a variety of human blood components. The spectral elimination method applies the principle of elimination method in mathematics to the noninvasive quantitative analysis of human blood components by spectral method, reduces the influence of non-target components on the detection of target components, and improves the accuracy of noninvasive quantitative analysis of human blood components.
View Article and Find Full Text PDFNeutrophil DREAM come true: The not-so-impossible quest for mechanisms of neutrophil function and heterogeneity.
J Exp Med
January 2022
Marsico Lung Institute and the Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, NC.
Article Synopsis
- Neutrophils display a diverse range of functions and responses, prompting increasing scientific interest in understanding this variability.
- A study by Li et al. highlights the role of a transcriptional repressor called DREAM in controlling how neutrophils adhere to blood vessel walls and migrate into tissues.
- This research sheds light on the underlying mechanisms contributing to the diverse responses of neutrophils during inflammation.
Neutrophil DREAM promotes neutrophil recruitment in vascular inflammation.
J Exp Med
January 2022
Department of Pharmacology, University of Illinois at Chicago College of Medicine, Chicago, IL.
The interaction between neutrophils and endothelial cells is critical for the pathogenesis of vascular inflammation. However, the regulation of neutrophil adhesive function remains not fully understood. Intravital microscopy demonstrates that neutrophil DREAM promotes neutrophil recruitment to sites of inflammation induced by TNF-α but not MIP-2 or fMLP.
View Article and Find Full Text PDFBackground: Based on preclinical work, we found that combination of poly (ADP-ribose) polymerase (PARP) inhibitors with drugs that inhibit the homologous recombination repair (HRR) pathway (such as PI3K inhibitors) might sensitise HRR-proficient epithelial ovarian cancers to PARP inhibitors. We aimed to assess the safety and identify the recommended phase 2 dose of the PARP inhibitor olaparib in combination with the PI3K inhibitor alpelisib in patients with epithelial ovarian cancer and in patients with breast cancer.
Methods: In this multicentre, open-label, phase 1b trial following a 3 + 3 dose-escalation design, we recruited patients aged 18 years or older with the following key eligibility criteria: confirmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of high-grade serous histology; confirmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of any histology with known germline BRCA mutations; confirmed diagnosis of recurrent breast cancer of triple-negative histology; or confirmed diagnosis of recurrent breast cancer of any histology with known germline BRCA mutations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!